Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
23.56
-0.09 (-0.38%)
At close: Apr 28, 2026, 4:00 PM EDT
23.42
-0.14 (-0.59%)
After-hours: Apr 28, 2026, 7:38 PM EDT
Legend Biotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2017 |
| Operating Revenue | 1,029 | 627.3 | 285.1 | 116.68 | 65.4 | Upgrade
|
| Other Revenue | - | - | - | 0.33 | 3.42 | Upgrade
|
| Revenue | 1,029 | 627.3 | 285.1 | 117.01 | 68.83 | Upgrade
|
| Revenue Growth (YoY) | 64.02% | 120.03% | 143.66% | 70.00% | -8.23% | Upgrade
|
| Cost of Revenue | 822.8 | 648.1 | 526.4 | 401.01 | 313.35 | Upgrade
|
| Gross Profit | 206.1 | -20.8 | -241.3 | -284.01 | -244.52 | Upgrade
|
| Selling, General & Admin | 341.6 | 284.3 | 201 | 174.05 | 149.5 | Upgrade
|
| Other Operating Expenses | 1 | - | 85.8 | - | - | Upgrade
|
| Operating Expenses | 342.6 | 284.3 | 286.8 | 174.05 | 149.5 | Upgrade
|
| Operating Income | -136.5 | -305.1 | -528.1 | -458.05 | -394.02 | Upgrade
|
| Interest Expense | -21.4 | -21.6 | -21.8 | -10.8 | -0.9 | Upgrade
|
| Interest & Investment Income | 40.1 | 61.2 | 54.5 | 8.18 | 0.97 | Upgrade
|
| Currency Exchange Gain (Loss) | -168.8 | 109.3 | -28.2 | -9.88 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 4 | 2.5 | 3.4 | 24.22 | -12.27 | Upgrade
|
| EBT Excluding Unusual Items | -282.6 | -153.7 | -520.2 | -446.33 | -406.22 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | 0.6 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.97 | Upgrade
|
| Asset Writedown | - | -4.4 | - | - | - | Upgrade
|
| Pretax Income | -282.6 | -158.1 | -520.2 | -445.72 | -407.2 | Upgrade
|
| Income Tax Expense | 14.2 | 18.9 | -1.9 | 0.63 | -3.61 | Upgrade
|
| Net Income | -296.8 | -177 | -518.3 | -446.35 | -403.58 | Upgrade
|
| Net Income to Common | -296.8 | -177 | -518.3 | -446.35 | -403.58 | Upgrade
|
| Shares Outstanding (Basic) | 184 | 183 | 176 | 159 | 141 | Upgrade
|
| Shares Outstanding (Diluted) | 184 | 183 | 176 | 159 | 141 | Upgrade
|
| Shares Change (YoY) | 0.80% | 3.84% | 10.71% | 12.91% | 19.21% | Upgrade
|
| EPS (Basic) | -1.61 | -0.97 | -2.94 | -2.81 | -2.87 | Upgrade
|
| EPS (Diluted) | -1.62 | -0.97 | -2.94 | -2.81 | -2.87 | Upgrade
|
| Free Cash Flow | -128.8 | -158.1 | -413.4 | -222.21 | -240.66 | Upgrade
|
| Free Cash Flow Per Share | -0.70 | -0.86 | -2.35 | -1.40 | -1.71 | Upgrade
|
| Gross Margin | 20.03% | -3.32% | -84.64% | -242.73% | - | Upgrade
|
| Operating Margin | -13.27% | -48.64% | -185.23% | -391.48% | -572.49% | Upgrade
|
| Profit Margin | -28.85% | -28.22% | -181.80% | -381.48% | -586.38% | Upgrade
|
| Free Cash Flow Margin | -12.52% | -25.20% | -145.00% | -189.91% | -349.67% | Upgrade
|
| EBITDA | -127.1 | -294.4 | -517.4 | -445.41 | -385.88 | Upgrade
|
| EBITDA Margin | -12.35% | -46.93% | -181.48% | - | - | Upgrade
|
| D&A For EBITDA | 9.4 | 10.7 | 10.7 | 12.65 | 8.14 | Upgrade
|
| EBIT | -136.5 | -305.1 | -528.1 | -458.05 | -394.02 | Upgrade
|
| EBIT Margin | -13.27% | -48.64% | -185.23% | - | - | Upgrade
|
| Revenue as Reported | 1,029 | 627.3 | 285.1 | 117.01 | 68.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.